NGS analysis in Marfan syndrome spectrum: Combination of rare and common genetic variants to improve genotype-phenotype correlation analysis

The diagnosis of Marfan spectrum includes a large number of clinical criteria. Although the identification of pathogenic variants contributes to the diagnostic process, its value to the prediction of clinical outcomes is still limited. An important novelty of the present study is represented by the statistical approach adopted to investigate genotype-phenotype correlation. The analysis has been improved considering the extended genetic information obtained by Next Generation Sequencing (NGS) and combining the effects of both rare and common genetic variants in an inclusive model. To this aim a cohort of 181 patients were analyzed with a NGS panel including 11 genes associated with Marfan spectrum. The genotype-phenotype correlation was also investigated considering the possibility to predict presence of a pathological mutation in Marfan syndrome (MFS) main genes based only on the analysis of phenotypic traits. Results obtained indicate that information about clinical traits can be summarized in a new variable that resulted significantly associated with the probability to find a pathological mutation in MFS main genes. This is important since the choice of the genetic test is often influenced by the phenotypic characterization of patients. Moreover, both rare and common variants were found to significantly contribute to clinical spectrum and their combination allowed to increase the percentage of phenotype variability that could be explained based on genetic factors. Results highlight the opportunity to take advantage of the overall genetic information obtained by NGS data to have a better clinical classification of patients.

[1]  C. Gravholt,et al.  Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study). , 2018, The American journal of cardiology.

[2]  M. Desai,et al.  Bicuspid aortic valve: Basics and beyond , 2018, Cleveland Clinic Journal of Medicine.

[3]  P. Pharoah,et al.  Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study , 2018, Journal of Medical Genetics.

[4]  M. Crespo-Leiro,et al.  The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome , 2018, Orphanet Journal of Rare Diseases.

[5]  A. Child.  Non-cardiac manifestations of Marfan syndrome. , 2017, Annals of cardiothoracic surgery.

[6]  B. Loeys,et al.  Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome. , 2017, Annals of cardiothoracic surgery.

[7]  J. A. A. Reyes,et al.  Variante genética del síndrome de Stickler , 2017 .

[8]  B. Landis,et al.  Genotype–phenotype correlations in Marfan syndrome , 2017, Heart.

[9]  E. Martínez-Quintana,et al.  Novel Marfan Syndrome-Associated Mutation in the FBN1 Gene Caused by Parental Mosaicism and Leading to Abnormal Limb Patterning , 2017, Molecular Syndromology.

[10]  Toshiyuki Yamamoto,et al.  A novel COL1A1 mutation in a family with osteogenesis imperfecta associated with phenotypic variabilities , 2017, Human Genome Variation.

[11]  Eva Loth,et al.  Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges , 2016, Front. Psychiatry.

[12]  A. Zwinderman,et al.  UvA-DARE ( Digital Academic Repository ) Marfan syndrome : Getting to the root of the problem , 2015 .

[13]  B. Loeys,et al.  Marfan Syndrome and Related Disorders: 25 Years of Gene Discovery , 2016, Human mutation.

[14]  L. Zhang,et al.  The genetics and pathogenesis of thoracic aortic aneurysm disorder and dissections , 2016, Clinical genetics.

[15]  F. Glorieux,et al.  Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment. , 2016, Bone.

[16]  A. Althouse.  Adjust for Multiple Comparisons? It's Not That Simple. , 2016, The Annals of thoracic surgery.

[17]  B. Loeys.  The search for genotype/phenotype correlation in Marfan syndrome: to be or not to be? , 2016, European heart journal.

[18]  K. Kosaki,et al.  Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24–32 , 2016, Heart and Vessels.

[19]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[20]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[21]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[22]  L. Baudhuin,et al.  Decreased frequency of FBN1 missense variants in Ghent criteria-positive Marfan syndrome and characterization of novel FBN1 variants , 2015, Journal of Human Genetics.

[23]  D. Charteris,et al.  Molecular pathogenesis and management strategies of ectopia lentis , 2014, Eye.

[24]  Iuliana Ionita-Laza,et al.  Sequence kernel association tests for the combined effect of rare and common variants. , 2013, American journal of human genetics.

[25]  F. Dudbridge.  Power and Predictive Accuracy of Polygenic Risk Scores , 2013, PLoS genetics.

[26]  E. Arbustini,et al.  The new Ghent criteria for Marfan syndrome: what do they change? , 2012, Clinical genetics.

[27]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[28]  F. Luo,et al.  Recent molecular biological progress in Marfan syndrome and Marfan-associated disorders , 2010, Ageing Research Reviews.

[29]  Laurence Faivre,et al.  The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.

[30]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[31]  E. Arbustini,et al.  Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24–32 mutation , 2009, European Journal of Human Genetics.

[32]  P. Robinson,et al.  The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome , 2008, American journal of medical genetics. Part A.

[33]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[34]  R. Pyeritz,et al.  Marfan syndrome and related disorders. , 2008, The Annals of thoracic surgery.

[35]  M Claustres,et al.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. , 2007, American journal of human genetics.

[36]  K. Rommel,et al.  Identification of 29 novel and nine recurrent fibrillin‐1 (FBN1) mutations and genotype–phenotype correlations in 76 patients with Marfan syndrome , 2005, Human mutation.

[37]  R. Hennekam.  Severe infantile Marfan syndrome versus neonatal Marfan syndrome , 2005, American journal of medical genetics. Part A.

[38]  G. Pals,et al.  Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome , 2004, Human mutation.

[39]  Uta Francke,et al.  Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. , 2002, American journal of human genetics.

[40]  B. Giusti,et al.  Fibrillin‐1 (FBN1) gene frameshift mutations in Marfan patients: genotype–phenotype correlation , 2001, Clinical genetics.

[41]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[42]  P. Green,et al.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment. , 1998, Genome research.

[43]  H. Dietz,et al.  Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. , 1995, Human molecular genetics.

[44]  D. Saville.  Multiple Comparison Procedures: The Practical Solution , 1990 .

[45]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[46]  P. Rocha Cabrera,et al.  Genetic variant of Stickler's syndrome. , 2018, Archivos de la Sociedad Espanola de Oftalmologia.

[47]  P. Robinson,et al.  Congenital heart disease Cardiovascular manifestations in men and women carrying a FBN 1 mutation , 2010 .

[48]  Ira M. Hall,et al.  BEDTools: a flexible suite of utilities for comparing genomic features , 2010, Bioinform..

[49]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[50]  Flemming Skovby,et al.  Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype–phenotype correlations in FBN1 exons 24–40 , 2001, European Journal of Human Genetics.